MONTREAL, June 25, 2019 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF), a leading specialty pharmaceutical company with a strong North American commercial platform, announces that Adele M. Gulfo has joined the Company’s Board of Directors, …
Latest News From Lumira Ventures
Medexus Pharmaceuticals Announces Normal Course Issuer Bid
MONTREAL, May 14, 2019 — Medexus Pharmaceuticals Inc. (the “Company”) (TSXV: MDP, OTCQB: PDDPF) announced today it has submitted to the TSX Venture Exchange (the “Exchange”) a notice of its intention to make a normal course issuer bid (the “Bid”). Provided …
Medexus Pharmaceuticals Launches New Dosage for Treatment of Rheumatoid Arthritis, Psoriasis & Psoriatic Arthritis in Canada
MONTREAL, May 7, 2019 — Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF), today announced the launch of a new Metoject® Subcutaneous 15mg dose in Canada. Metoject Subcutaneous is a pre-filled syringe of methotrexate with a pre-attached subcutaneous …
Medexus Pharmaceuticals Inc. (CVE:MDP) Revenue Increases 512% Year-over-Year
March 27, 2019 — Medexus Pharmaceuticals Inc (CVE:MDP) (FRA:P731) CEO Ken d’Entremont provides an overview of the company and highlights its recent financial reporting. The company is the results of the recent amalgamation of three specialty pharmaceutical companies: Pediapharm Inc, …